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MiR-214 increases the sensitivity of breast
cancer cells to tamoxifen and fulvestrant
through inhibition of autophagy
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Abstract
Background: Tamoxifen (TAM) and fulvestrant (FUL) are the major drugs for patients with estrogen receptor-
positive (ER+) breast cancers. However, the development of endocrine resistance is the impediment for successful
treatment. We aimed to explore the mechanisms of endocrine resistance and therapeutic strategy for overcoming
resistance against TAM and FUL.
Methods: Experiments were performed in ER+ and estrogen/TAM-sensitive MCF7 cells and antiestrogen-resistant
MCF7/LCC9 cells. The expression of miR-214 and uncoupling protein 2 (UCP2) was determined by RT-qPCR and
Western blot in breast cancer cells and human breast cancer tissue specimens. Cell autophagy was examined by
fluorescent probe monodansyl cadaverine (MDC) and GFP-LC3-II-positive punctate identified by confocal
microscopy. Apoptotic cells were determined by Annexin V-FITC/PI staining. The potential regulatory target of
miR-214 was determined by prediction tool, target protein expression and luciferase reporter assay.
Results: 4-OHT/FUL treatment resulted in induction of apoptosis as well as autophagy in breast cancer cells.
Autophagy might be the major cause of endocrine resistance to 4-OHT or FUL. MiR-214 increased the sensitivity of
breast cancer cells to the 4-OHT/FUL-induced apoptosis through inhibition of autophagy. Importantly, a negative
correlation was established between miR-214 and UCP2 in human breast cancer tissue specimens assayed by
RT-qPCR. UCP2 was identified to be a direct target of miR-214. Further study in MCF7/LCC9 cells indicated that
endocrine resistance might arise from activation of the PI3K-Akt-mTOR pathway, thereby inducing autophagy by
overexpression of UCP2.
Conclusion: MiR-214 increased the sensitivity of breast cancer cells to TAM and FUL through inhibition of
autophagy by targeting UCP2. MiR-214 shows potential as a novel therapeutic strategy for overcoming endocrine
resistance in ER+ breast cancers.
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Background
Breast cancer is one of the most prevalent cancers in
women worldwide, with almost 1.2 million new cases diag-
nosed each year [1]. Breast cancers are classified based on
the expression of hormone receptors: estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth receptor 2 (HER2). Among those patients, about
70 % of cases express ER. In patients with metastatic breast
cancer, the percentage of cases with ER reaches 75 % [2].
Targeting estrogen and its receptors is therefore an import-
ant strategy in endocrine therapies for breast cancers.
Commonly used drugs include (a) tamoxifen (TAM) and
(b) fulvestrant (FUL). TAM has been used as an anti-
estrogen agent for many years. TAM physically competes
with estrogens to bind to ER, thereby preventing the prolif-
erative stimuli of estrogens [3]. Unlike TAM, FUL is a pure
ER antagonist which competitively binds to ER, leading to
its downregulation in cancer cells. FUL is specifically indi-
cated for treatment of postmenopausal patients with ER+
metastatic breast cancer [4, 5].
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Although these drugs are initially effective, overall
clinical benefit from use of them is often eventually
limited by the development of endocrine resistance.
TAM, for instance, is not effective in approximately
30 % of patients and resistance is observed in 50 % of
patients eventually after treatment [6]. After prolonged
therapy with FUL, therapy resistance eventually develops
in most of patients and recurs with metastatic disease
[5, 7]. Multiple mechanisms responsible for endocrine
resistance are recognized, such as deregulation of the
ER pathway itself, alterations in cell cycle and survival
molecules, and altered expression of miRNAs [8, 9].
Recently, the noteworthy mechanism of endocrine re-
sistance is the increase of autophagy and apoptosis in
the ER+ breast cancers following TAM treatment [10].
In fact, autophagy and apoptosis pathways are tightly
connected with each other by substantial interplays,
enabling the coordinated regulation of cell fates by
these two pathways. Studies have shown that autoph-
agy occurs when the apoptotic machinery is imper-
fect, detailed mechanisms underlying are not clearly
understood [11, 12]. Autophagy is an evolutionarily
conserved mechanism of cellular self-digestion in
which proteins and organelles are degraded through
delivery to lysosomes. The process of autophagy path-
way is regulated by a variety of signaling molecules
[13]. Since autophagy is involved in the process of
pathological disorders with a shift in balance between
cell death and survival in response to TAM, increase
of autophagy was thus recognized as an important
mechanism of TAM resistance [14]. Inhibition of au-
tophagy might potentiate resensitization of previously
antiestrogen resistant breast cancer cells [6]. However,
a balance might exist between autophagy and apop-
tosis in response to the endocrine therapy. The key
point in the determination of cell fate appears to be
affected by the status of cancer cells in autophagy or
apoptosis [15].
MiRNAs are a class of short, endogenous, noncoding
RNAs (~20–24 nucleotides) that regulate the expression
of a wide variety of genes. Through base pairing with the
3′-untranslated region (3′UTR) of target genes, miRNAs
were found to enhance mRNA degradation or inhibit
posttranscriptional translation [16, 17]. Mountains of re-
ports showed that miRNA alteration or dysfunction
might play important roles in tumorigenesis and cancer
metastasis by the way of regulating cancer cell prolifera-
tion, differentiation, apoptosis and invasion [18]. Not-
ably, miRNAs were found to function in the regulation
of autophagy. For instance, miR-101 was identified as a
potent inhibitor of basal, etoposide- and rapamycin-
induced autophagy [19]. MiR-214 is often dysregulated
in various cancers and its functions vary largely with tis-
sue types. The upregulation of endogenous miR-214 has
been linked with increased proliferation, migration, inva-
sion, extravasation and metastasis in specific cancer
types, such as pancreatic, cervical, hepatocellular, gastric,
prostate and ovarian cancer [20]. By contrast, the down-
regulation of this miR has been associated with cancer
progression and metastasis in some other caner types,
such as breast cancers, suggesting that tight regulation
of miR-214 is important for cellular function [21, 22]. In
addition, miR-214 has been shown to induce apoptosis
in some cancer types [23]. In our pilot study, miR-214
was found downregulated in human breast cancer tissue
specimens. Using ER+ breast cancer cell lines, miR-214
increased the sensitivity of cancer cells to TAM and FUL
through inhibition of autophagy. Upregulation of miR-
214 led to the inhibition of breast cancer growth and in-
vasion [22]. MiR-214 was thus considered as a tumor
suppressor in many cancers. However, functional rele-
vance of these findings and mechanisms has not been
fully addressed. In this study, we examined the effects of
miR-214 on sensitivity of breast cancer cells to TAM
and FUL in the ER+ and estrogen/TAM-sensitive MCF7
cells and antiestrogen-resistant MCF7/LCC9 cells. The
biochemical mechanisms behind the effects of miR-214
were then investigated.
Methods
Human breast cancer tissue specimens
This section of experiment was approved by the Institu-
tional Review Board of the Chinese Academy of Medical
Sciences Cancer Institute, and written informed con-
sents were obtained from all patients. No patients re-
ceived any type of endocrine therapy. Twenty pairs of
breast cancer tissue specimens and adjacent normal mu-
cosa were obtained from Chinese Academy of Medical
Sciences Cancer Hospital (Beijing, China). Each pair of
cancer specimen and adjacent normal tissue was con-
firmed by pathological analysis. All tissues were immedi-
ately frozen in liquid nitrogen after surgical removal
until use for real-time-qPCR analysis.
Cell culture and drug treatment
Human breast cancer cell line MCF7 was purchased
from American Type Culture Collection (ATCC, Rockville,
MD). MCF7 is the ER positive and estrogen/TAM-sensitive
cell line. MCF7 cells were grown in DMEM medium
supplemented with 10 % fetal bovine serum (FBS)
and 0.01 mg/ml insulin at 37 °C in a humid atmos-
phere (5 % CO2-95 % air). MCF7/LCC9 cell line is a
fully antiestrogen-resistant MCF7 variant exhibiting
cross resistance to FUL and TAM [24]. MCF7/LCC9 was
provided by Dr. Robert Clarke (Georgetown University).
MCF7/LCC9 cells were maintained in phenol-red free
DMEM containing 5 % dextran charcoal-stripped FBS
(DCC-FBS) and 100 μg/ml penicillin.
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Prior to treatment, cells were exposed to 5 % DCC-
FBS for 48 h (serum-starved). Cells were then treated
with 5 μΜ 4-hydroxytamoxifen (4-OHT, Sigma-Aldrich)
or 1 μM FUL (Sigma-Aldrich) for 48 or 72 h in the pres-
ence or absence of 5 mM 3-methyladenine (3-MA,
Sigma-Aldrich). 0.1 % ethanol was used as vehicle control
(0.01 % final volume).
Plasmids construction and cell transfection
To produce UCP2 expression plasmid, full length of
UCP2 coding region was amplified by PCR using
sequence-specific primers (forward: 5’-cgcGGATCCag-
gacgtagcaggaaatcagc-3’, reverse: 5’-gcTCTAGAagaggtgat-
caggtcagcag-3’, containing restriction sites for BamH1
and XbaI respectively). The double digested cDNA was
inserted into pcDNA3.1-HisC plasmid and confirmed by
sequencing. For UCP2 knockdown assay, the siRNA
against UCP2 was synthesized by GenePharma (Shanghai,
China). The oligonucleotide sequences were 5’-GCACC-
GUCAAUGCCUACAATT-3’. MiR-214 mimics and in-
hibitors were also purchased from GenePharma
(Shanghai, China). Transient transfection of UCP2 plas-
mid and siRNA or miRNA was performed with Lipofec-
tamine 2000 (Invitrogen) according to manufacturer’s
instructions. MCF7 or MCF7/LCC9 cells were trans-
fected either with 200 nM UCP2 siRNA or 100 nM
miR-214 mimics/inhibitors for 48 h. Corresponding
negative control was concurrently used in all experi-
mental system. Cells were harvested for RT-PCR or
Western blotting analysis.
RNA extraction and RT-qPCR
Total RNA was extracted using TRIzol (Invitrogen) in
accordance with manufacturer’s protocol. Reverse tran-
scription of total miRNA was performed by using a miS-
cript reverse transcription kit (Qiagen). MiScript SYBR
Green PCR kit (Qiagen) together with a pair of miR-214
specific primers was used for mature miRNA detection.
RNU6B was used as an internal normalized reference.
For detection of UCP2 mRNA expression, total RNA
was reversely transcribed by using SuperScript III
First-Strand Synthesis System (Invitrogen) according
to manufacturer’s instruction. Real-time PCR was per-
formed in triplicate in an ABI 7900HT real-time PCR
system (Applied Biosystems) with a 20 μl reaction mixture
containing Brilliant II SYBR Green qPCR master mix and
300 nM UCP2 primers. Primer sequences for UCP2 were
5’-cgcatcggcctgtatgattc-3’ and 5’- cataggtcaccagctcagc-
3’. Primer sequences for GAPDH were 5’-gagtcaacg-
gatttggtcgt-3’ and 5’-ttgattttggagggatctcg-3’. The thermal
cycling was initiated by polymerase activation step for
10 min at 95 °C followed by 40 cycles of denaturation
(95 °C for 30 s) and annealing/extension (60 °C for 1 min).
Relative expression of UCP2 was normalized to GAPDH
as an internal control and determined by a previously de-
scribed method [25].
Western blotting analysis
Cells were harvested and lysed in radioimmune precipi-
tation assay (RIPA) buffer. Protein was extracted and
concentration was determined by using a BCA kit
(Thermo Fisher Scientific). Equal amounts of cell lysates
were resolved by SDS-PAGE and transferred to PVDF
membranes (Millipore). After blocking in 5 % nonfat
milk for 1 h, the membranes were immunoblotted
overnight at 4 °C with primary antibodies against LC3,
beclin-1, caspase-9, Bcl-2, PARP (Cell Signaling Tech-
nology) and Bax (Santa Cruz) followed by incubation
with polyclonal HRP-conjugated secondary antibodies
for 1 h at room temperature. Immunoreactive prod-
ucts were visualized by chemiluminescence (Pierce
Biotechnology) and quantified by densitometry using
Quantity One software. Densitometric analyses of
bands were normalized with β-actin functioning as a
loading control.
Cell viability assay
MCF7 cells seeded in 6-well plate were transfected with
100 nM negative control or miR-214 mimics and inhibi-
tors for 24 h. Cells were trypsinized into 96-well plates
at a density of 8 × 103 cells/well and then treated with 5
μΜ 4-OHT, or 1 μM FUL for 72 h.. Cell viability was
estimated by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) assay.
Annexin V-FITC/PI staining assay
MCF7 cells grown in 6-well plate were transfected with
2 μg UCP2 expression plasmid, 200 nM UCP2 siRNA or
100 nM miR-214 mimics and inhibitors as well as corre-
sponding negative control for 24 h. Cells were then
treated with 5 μM 4-OHT for additional 48 h in 5 %
DCC-FBS/DMEM. Cells were harvested and washed
with cold PBS. Levels of phosphatidylserine on cell sur-
face were quantitatively estimated by using Annexin V-
fluorescein isothiocyanate (FITC) and Propidium Iodide
(PI) apoptosis detection kit according to manufacturer’s
instruction (Bioscience). Apoptotic cells were analyzed
in a flow cytometer (Guava easyCyte) using FL1 (excita-
tion 488 nm, green) and FL3 (excitation 585 nm, red)
channels. A minimum of 10,000 events was collected for
each sample. Results were expressed as percentage of
apoptotic cells relative to total cells.
Cell autophagy analysis
Cells were transfected with GFP-LC3 plasmid (Addgene)
and then treated with 0.1 % v/v ethanol vehicle or 5 μM 4-
OHT or 1 μM FUL for 48 h. GFP-LC3-II-positive punc-
tate pattern was observed under confocal microscope
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(Leica TCS SP5) equipped with oil immersion lens (40×)
with 405- and 488-nm excitation lasers. Numbers of
autophagosomes were counted by using the Image J pro-
gram (National Institutes of Health).
Staining of autophagic vacuoles by monodansyl
cadaverine (MDC)
Fluorescent probe MDC is a selective marker for acidic
vesicular organelles to evaluate autophagy. MCF7 cells
grown on coverslips were treated with 5 μM 4-OHT for
48 h. Cells were then exposed to 50 μM MDC (Sigma-
Aldrich) at 37 °C for 15 min in the dark for staining.
After washing with PBS, cells were visualized under
fluorescence microscope (Leica, Wetzlar, Germany).
Plasmid construction and luciferase reporter assay
To generate luciferase constructs for evaluating miRNA ac-
tivity, 3’ UTR of UCP2 gene was amplified using the
primers whose sequences were 5’-gcGAGCTCgcctctcctgctg
ctgacc-3’and 5’-gcTCTAGAatggatgacaagtgggctagg-3’. PCR
was performed with genomic DNA and digested by both
Sac I and Xba I and cloned into a modified pGL3-control
vector pISO provided by Dr. Zhihua Liu [26]. A pair of
primer 5’-gcGAGCTCgcctctcctgatactgacctgatcacc-3’ and 5’-
gcTCTAGAatggatgacaagtgggctaggctggg-3’ was used to gen-
erate mutation in the seed region binding sites. Wild type
and mutant inserts were confirmed by sequencing.
For luciferase reporter assay, MCF7 cells seeded in a
96-well plate were co-transfected with firefly luciferase
constructs (100 ng) and 40 nM miRNA mimics using li-
pofectamine 2000 reagent. Cells were also transfected
with 10 ng of pRL-SV40 plasmid to monitor transfection
efficiency. 36 h after transfection, firefly luciferase activ-
ity was evaluated by using a dual-luciferase reporter
assay system (Promega Corporation). Renilla luciferase
activity was evaluated to normalize firefly luciferase ac-
tivity for each sample. Transfections were performed in
triplicate and the experiments were repeated twice.
Immunofluorescence staining analysis
MCF7 cells grown on cover-slips were fixed in 4 % para-
formaldehyde for 10 min at room temperature. Cells
were washed in PBS, blocked with 5 % bovine serum
albumin (BSA) supplemented with 0.3 % Triton X-100
in PBS for 1 h. Cells were incubated with primary anti-
body (UCP2, Santa Cruz) in 1 % BSA at 4 °C overnight.
After washing with PBS, cells were incubated with
Rhodamine-labeled anti-goat secondary antibody (ZSGB-
Bio, Beijing) in 1 % BSA for 1 h at room temperature.
Cells were washed and cellular nuclei were stained with
Hoechst 33342 (Sigma-Aldrich) for 10 min. Images were
acquired under confocal microscope (TCS SP5, Leica).
Statistical analysis
All data are presented as mean ± SD. Statistical differ-
ences were evaluated by analysis of variance (ANOVA)
followed by Dunnett (multiple comparisons to the same
control) post hoc tests. Values of P < 0.05 were considered
as statistically significant.
Results
4-OHT/FUL treatment induces autophagy in breast cancer
cells
Human ER+ MCF7 cells were exposed to 5 μΜ 4-OHT,
an active metabolite of TAM, or 1 μΜ FUL for different
time and then the characteristics of autophagy was ana-
lyzed. Beclin-1 is one of markers that critically indicate
the process of autophagosomic-lysosomal degradation of
proteins activated in response to pathological disorders.
4-OHT and FUL treatment increased the expression of
beclin-1 time-dependently. The increase of beclin-1
reached a peak at 12 h after exposure and remained at
high levels up to 48 h (Fig. 1a). LC3-II, the cleaved and
lipidated form of the microtubule associated protein
light chain 3 (MAP1LC3), is the hallmark protein signi-
fying the increase of autophagy. 4-OHT/FUL treatment
led to elevation of LC3-II, which reached plateau during
time from 12 to 48 h.
The 4-OHT/FUL-induced autophagy was also seen
after staining with acidic vesicular organelles (AVOs).
Figure 1b showed the morphological change of autophagy
in the 4-OHT/FUL-treated cells. A significant increase of
MDC fluorescent intensity was observed in the 4-OHT/
FUL-treated cells, showing an increased fraction of cells
with punctate staining distributed within cytoplasm or
perinuclear regions. We added 3-MA, an autophagy in-
hibitor, to the 4-OHT/FUL-treated cells. The formation of
autophagosomes was obviously inhibited (Fig. 1b).
(See figure on previous page.)
Fig. 1 4-OHT or FUL induced autophagy in breast cancer cells. a MCF7 cells were exposed to 5 μM 4-OHT or 1 μM FUL for the indicated time.
Western blotting was performed to determine the expressions of LC3 and Beclin-1. Bar graphs indicated relative levels of LC3-II and Beclin-1
normalized to β-actin. Data represent mean ± SD of three experiments. *P < 0.05, **P < 0.01 vs. vehicle control. b MCF7 cells seeded on coverslips
were treated with 5 μM 4-OHT or 1 μM FUL for 48 h. After staining with MDC, cells were imaged under a fluorescence microscope (scale bar = 50 μm),
with a magnified image showing punctate pattern. c MCF7 cells were transfected with GFP-LC3 for 24 h and then were treated with 5 μM 4-OHT or
1 μM FUL with or without 5 mM 3-MA for 48 h. Cells were imaged under a confocal microscopy, scale bar = 50 μm (up) or 10 μm (bottom). Numbers
of GFP-LC3 puncta per cell were counted. **P < 0.01 vs. vehicle control, ##P < 0.01 vs. TAM/FUL treatment, n = 10 cells. Data represent mean ± SD of
three experiments
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MCF7 cells were transfected with GFP-LC3 plasmid
and GFP-LC3-II puncta was analyzed in autophagic
cells. The number of autophagosomes (GFP-LC3-II dots)
was then counted in the 4-OHT/FUL-treated cells. 4-
OHT/FUL treatment significantly increased GFP-LC3
puncta in MCF7 cells (Fig. 1c). However, in the presence
of 3-MA, the formation of autophagosomes was inhibited
(Fig. 1c, bottom, P < 0.01, vs. vehicle control).
MiR-214 increases the 4-OHT/FUL-induced cell apoptosis
By binding to ER, the effect of 4-OHT/FUL mainly de-
pends on the activity of apoptotic induction. In order to
find miRNAs that sensitize the 4-OHT/FUL-induced
apoptosis, cell proliferation and apoptosis were examined
in the miRNAs-transfected MCF7 cells. MiR-214 was con-
sidered as an important mediator in the sensitization of
the 4-OHT/FUL-induced apoptosis. The proliferation of
MCF7 cells was inhibited by 16.7 ± 1.1 % by 4-OHT
(Fig. 2a, P < 0.01 vs. vehicle control) and 30.0 ± 0.6 % by
FUL (P < 0.01 vs. vehicle control). When MCF7 cells were
transfected with miR-214 mimics, the percentage of inhib-
ition by 4-OHT or FUL was significantly increased as
compared to negative control cells (33.3 ± 2.1 % by 4-
OHT, and 47.8 ± 1.1 % by FUL, respectively, P < 0.01).
These results indicated that MCF7 cells transfected with
miR-214 mimics exhibited higher sensitivity to 4-OHT/
FUL than the cells transfected with negative control
miRNA. However, miR-214 inhibitor did not significantly
affect the viability of MCF7 cells treated with 4-OHT/FUL.
MiR-214 increased the effect of the 4-OHT-
induced apoptosis. As shown in Fig. 2b, the percent-
age of apoptotic cells was 12.4 ± 2.6 % (P < 0.05 vs.
negative control) in MCF7 cells exposed to 4-OHT.
Cells transfected with miR-214 mimics demonstrated
higher levels of apoptosis than negative control cells
(P < 0.05). When these cells were exposed to 4-OHT,
the percentage of apoptotic cells was significantly in-
creased to 23.2 ± 2.9 % (P < 0.01 vs. negative control).
There was a significant difference in the percentage of
apoptotic cells between the miR-214-transfected cells and
negative control cells in response to 4-OHT treatment
(Fig. 2b, P < 0.05).
The effect of miR-214 mimics in improving the
sensitization of breast cancer cells to the 4-OHT-induced
apoptosis was further evaluated at the protein levels. Both
4-OHT and FUL significantly increased the ratio of Bax/
Bcl-2, the levels of cleaved PARP and cleaved caspase-9 in
MCF7 cells. Cells transfected with miR-214 mimics had
higher levels of apoptotic proteins than negative control
cells in response to 4-OHT or FUL exposure (Fig. 2c,
P < 0.01 vs. vehicle control). Since autophagy plays a
prosurvival role and contributes to drug resistance, it
is likely that miR-214 mimics might enhance the sensitiv-
ity of breast cancer cells to the 4-OHT/FUL-induced
apoptosis by the inhibition of autophagy. We analyzed the
specific autophagy marker LC3 in the miR-214 mimics-
transfected cells. As compared to control cells, the 4-
OHT/FUL-induced cleavage of LC3-Ι into LC3-II was sig-
nificantly attenuated in the miR-214 mimics-transfected
cells (Fig. 2c, P < 0.01 vs. negative control).
MiR-214 inhibits both basal and the 4-OHT/FUL-induced
autophagy
The induction of autophagy by 4-OHT/FUL was further
evidenced by the elevated levels of cleaved LC3-II and
beclin-1 (Fig. 3a). In fact, the level of miR-214 in these
4-OHT/FUL-treated cells was obviously reduced as
compared with the vehicle control cells (Fig. 3b). These
results implied that miR-214 might play important roles
in the regulation of the 4-OHT/FUL-induced autophagy.
Further evidence was found by Western blotting assay in
MCF7 cells transfected with miR-214 mimics or inhibi-
tors. As shown in Fig. 3c, the level of LC3-II was signifi-
cantly reduced in MCF7 cells overexpressing miR-214,
whereas miR-214 inhibitors stimulated the expression of
cleaved LC3-II (Fig. 3c). These results indicated that
miR-214 inhibited autophagy at the basal level. When cells
were exposed to 4-OHT or FUL, miR-214 mimics and in-
hibitors had opposite effects on autophagy. As shown in
Fig. 3d, in response to 4-OHT or FUL, the miR-214
mimics-transfected MCF7 cells demonstrated lower levels
of LC3-II than negative control cells (Fig. 3d, above). These
autophagic markers were dramatically augmented in the
MCF7 cells transfected with miR-214 inhibitors (Fig. 3d,
bottom). These results were also evidenced by analysis of
autophagosomes under confocal microscopy. The forma-
tion of autophagosomes (GFP-LC3 dots) was significantly
inhibited in the miR-214 overexpressing cells (Fig. 3e up).
(See figure on previous page.)
Fig. 2 MiR-214 increased the TAM/FUL-induced apoptosis in breast cancer cells. a MCF7 cells were transfected with 100 nM miR-214 mimics
(214 m) or inhibitors (214i) for 24 h. Cells were then treated with 5 μM 4-OHT or 1 μM FUL for 72 h. Cell viability was estimated by the MTT assay.
b MCF7 cells were transfected with 100 nM miR-214 mimics (214 m) or negative control (NC). Cells were then treated with or without 5 μM 4-OHT
for 48 h. Annexin V-PI double staining was performed by flow cytometry. Bar graphs indicated the percentage of apoptotic cells. Data represent
mean ± SD of three experiments. *P < 0.05, **P < 0.01 vs. negative control (NC), #P < 0.05 vs. negative control treated with 4-OHT (NC + 4-OHT)
(c) Western blotting was performed to analyze the expression of apoptotic proteins Bax, Bcl-2, c-PARP (cleaved PARP), cleaved-caspase-9 (c-capase-9)
and autophagic protein LC3-II. Bar graphs indicated relative levels of Bax/Bcl-2, c-PARP, c-capase-9 and LC3-II normalized to β-actin. *P< 0.05, **P < 0.01
vs. vehicle control, ##P< 0.01 vs. negative control (NC)
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On the contrary, the number of GFP-LC3 dots in the
MCF7 cells transfected with miR-214 inhibitors was obvi-
ously increased. The increase of GFP-LC3 dots was signifi-
cantly reduced by 3-MA (Fig. 3e bottom, P < 0.01).
UCP2 is a direct target of miR-214
Having established a link between miR-214 and autoph-
agy, we further investigated the mechanism of miR-214
by identifying its downstream targets. We employed the
TargetScan program to predict the potential target
genes. To our interest, UCP2, a mitochondrial protein
that has been implicated in the production of intracellu-
lar Reactive oxygen species (ROS), might be targeted by
miR-214. To evidence this hypothesis, we analyzed the
expression of miR-214 and UCP2 in human breast can-
cer tissue specimens. A potential correlation of miR-214
and UCP2 was observed in 20 pairs of human breast
cancer tissues and matched normal tissues. Lower level
of miR-214 was observed in most of cancer tissues (15/20,
75.0 %), while UCP2 mRNA was significantly upregulated
(17/20, 85.0 %) as compared with the matched normal tis-
sues (P = 0.0013 and P = 0.0022, respectively) (Fig. 4a, b).
Further analysis showed that the level of miR-214 was
negatively correlated with the elevation of UCP2 mRNA
(Pearson γ = -0.49, P = 0.028).
To identify the target gene of miR-214, MCF-7 cells
were transfected with miR-214 mimics or negative con-
trol. The level of UCP2 mRNA was significantly reduced
in the miR-214 overexpressing cells (Fig. 4c, d). The in-
hibitory effect of miR-214 on the expression of UCP2
protein was also analyzed by immunofluorescence assay.
Figure 4e showed the images of MCF7 cells with the
Rhodamine-labeled UCP2 protein located in mitochon-
dria. The fluorescence intensity was significantly reduced
by 33.1 ± 7.6 % in the miR-214 mimics-transfected cells
(P < 0.01 vs. negative control). In contrast, MCF7 cells
transfected with miR-214 inhibitors produced a sig-
nificant increase of 1.8 ± 0.3 fold in the fluorescence
intensity of UCP2 as compared with negative control
cells (P < 0.01 vs. negative control).
MiR-214 was found to downregulate UCP2 by target-
ing the site in 3’UTR of UCP2 gene determined by dual
luciferase reporter assay (Fig. 4f ). The binding of miR-
214 to the target site in the 3’UTR of UCP2 was identi-
fied by cloning the wild-type (WT) and mutant UCP2
3’UTR behind the luciferase gene in pISO vector. Co-
expression of UCP2-3’UTR constructs with miR-214
mimics in MCF7 cells resulted in an inhibition of the
relative luciferase activity by 83.7 ± 1.1 % (P < 0.01) as
compared with negative control miRNA mimics;
whereas miR-214 mimics did not significantly inhibit
luciferase activity in the cells expressing mutant
UCP2-3’UTR. These results suggested that miR-214
might directly bind to the 3’UTR of UCP2 and modu-
late UCP2 expression.
Overexpression of UCP2 contributes to endocrine
resistance to 4-OHT
Based on the observation of relevance between UCP2
and miR-214, we hypothesized that miR-214 might in-
crease the 4-OHT-induced apoptosis through inhibition
of UCP2. We explored the role of UCP2 in affecting the
4-OHT-induced apoptosis in breast cancer cells. UCP2
expression plasmids were constructed and then trans-
fected into MCF7 cells. The expression of UCP2 was an-
alyzed by RT-qPCR and Western blotting (Fig. 5a, b).
RNA interference assay was performed to knockdown
UCP2. Results showed that the level of UCP2 mRNA was
significantly reduced by 65.1 ± 6.2 % (Fig. 5c, P < 0.01).
Overexpression and knockdown of UCP2 by transfection
of UCP2 expression plasmid and siRNA were ana-
lyzed by immunofluorescence staining assay (Fig. 5d).
Transfection of UCP2 expression plasmids or UCP2
siRNA led to a pronounced increase or decrease of
Rhodamine-labeled fluorescence intensity as compared
with control cells (P < 0.05).
Subsequently, the apoptotic cells were determined by
Annexin V-Propidium Iodide (PI) staining by flow
cytometry. As shown in Fig. 5e, UCP2 siRNA led to a
significant increase of apoptosis in the presence or
absence of 4-OHT as compared to negative control
(P < 0.01). In contrast, UCP2 overexpression attenu-
ated both endogenous and the 4-OHT-induced apop-
tosis compared with empty vector control (P < 0.01).
These results indicated that downregulation of UCP2
increased the sensitivity of breast cancer cells to 4-
(See figure on previous page.)
Fig. 3 MiR-214 regulated autophagy at both basal and 4-OHT/FUL induced level. a MCF7 cells were treated with 5 μM 4-OHT or 1 μM FUL for
48 h. Western blotting was performed to analyze LC3 and Beclin-1. Bar graphs indicated relative levels of LC3-II and Beclin-1 normalized to
β-actin. **P < 0.01 vs. vehicle control. b The expression of miR-214 was analyzed by RT-qPCR. **P < 0.01 vs. vehicle control. c and d) MCF7 cells
were transfected with 100 nM miR-214 mimics (214 m) or inhibitors (214i) for 24 h, then were treated with or without 5 μM 4-OHT or 1 μM
FUL for 48 h. Western blotting was performed to analyze LC3-II normalized to β-actin. RT-qPCR was performed to analyze the level of miR-214
(c). *P < 0.05, **P < 0.01 vs. vehicle control, ##P < 0.01 vs. negative control (NC). e MCF7 cells were co-transfected with GFP-LC3 and 100 nM
miR-214 mimics or inhibitors for 48 h in the presence or absence of 5 mM 3-MA. Cells were imaged under a confocal microscopy (scale
bar = 10 μm). Numbers of GFP-LC3 puncta per cell were counted (*P < 0.05 **P < 0.01 vs. negative control, ##P < 0.01 vs. transfection of
miR-214 inhibitors (214i), n = 10). Data represent mean ± SD of three experiments
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Fig. 4 UCP2 was identified the target gene of miR-214. a RT-qPCR was performed to analyze the expression of miR-214 relative to RNU6 in 20
pairs of breast cancer tissues. b RT-qPCR was also performed to analyze the expression of UCP2 mRNA in breast cancer tissues. c, d) MCF7 cells
were transfected with 100 nM miR-214 mimics, then RT-qPCR was performed to analyze the expression of miR-214 and UCP2 mRNA. **P < 0.01
vs. negative control (NC). e MCF7 cells were transfected with 100 nM miR-214 mimics or inhibitors for 48 h. The expression and location of the
Rhodamine-labeled UCP2 were determined by the immunofluorescence assay. Hoechst 33342 was used to stain nuclei. Images were acquired by
confocal microscopy. f MCF7 cells were transfected with luciferase constructs and miR-214 mimics. The comparison of luciferase activity of
wild-type (WT) and mutant (MUT) UCP2 constructs was performed 36 h after transfection. Data was normalized to renilla activity. **P < 0.01 vs.
negative control (NC)
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Fig. 5 (See legend on next page.)
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OHT, whereas overexpression of UCP2 contributed to
acquired endocrine resistance to 4-OHT.
PI3K-Akt-mTOR pathway might be involved in the
induction of autophagy by overexpression of UCP2
We investigated the role of UCP2 in the autophagy that
confers endocrine resistance. TAM and FUL cross-
resistant MCF7/LCC9 cells were employed in the assays.
MCF7/LCC9 cells were transfected either with UCP2
plasmid or with siRNA and then exposed to 4-OHT
or FUL. High level of cleaved LC3-II was observed
in the UCP2 overexpressing cells, whereas low level
of active form of LC3-II was detected in the UCP2
knockdown cells. These results indicated that overexpres-
sion of UCP2 induced cell autophagy in the 4-OHT/FUL-
treated MCF7/LCC9 cells. Consistently, the ratio of Bax//
Bcl-2 was significantly elevated in the UCP2-knockdown
cells (Fig. 6a), indicating the increase of apoptosis. The in-
duction of autophagy by UCP2 was further determined by
the observation of punctate GFP-LC3 distribution in
breast cancer cells. Overexpression of UCP2 induced
prominent autophagy as indicated by enhanced GFP-LC3
dots. In contrast, knockdown of UCP2 inhibited the
formation of autophagesomes as shown by punctate
GFP-LC3, accounting for 38.3 ± 8.8 % of negative
control (Fig. 6b).
To investigate the signaling pathway of autophagy reg-
ulated by UCP2, MCF7/LCC9 cells were overexpressed
or knockdown UCP2 and then exposed to 4-OHT.
MCF7/LCC9 cells overexpressing UCP2 showed activa-
tion of Akt and mTOR in response to 4-OHT, whereas
the expressions of phospho-Akt and phospho-mTOR
were significantly decreased in the UCP2-knockdown
cells (Fig. 6c). Significant changes of non-phosphorylated
Akt and mTOR were not observed between the UCP2-
overexpressing and UCP2-knockdown cells. These results
indicated that the activation of the PI3K-Akt-mTOR
signaling pathway might be involved in the induction
of autophagy by overexpression of UCP2 in breast
cancer cells.
Discussion
The development of resistance to endocrine therapy is
the biggest challenge for treatment of breast cancers
with TAM or FUL. Endocrine resistance to TAM or FUL
was found to link with multiple reasons, such as loss of
ER, apoptosis resistance and altered expression of miR-
NAs [27]. Recently, studies have been focused on the ab-
errant regulation of autophagy in breast cancers. TAM/
FUL treatment led to apoptosis as well as autophagy in
the ER+ breast cancers [14]. Autophagy as a cytoprotec-
tive adaptive response usually occurs in the presence of
apoptosis inductors. Molecular analysis indicated that
Beclin-1, the key player in autophagy, can bind to Bcl-2
or another anti- apoptotic molecule, Bcl-xL. Beclin-1 is
therefore activates the initial stages of autophagy when it
is dissociated from Bcl-2 [28, 29]. In this study, miR-214
increased the sensitivity of breast cancer cells to the
TAM/FUL-induced apoptosis. Importantly, miR-214 in-
creased the TAM/FUL-induced apoptosis while inhibited
autophagy. Further study showed that miR-214 might
exert its inhibitory effect on autophagy by targeting
UCP2. This result was confirmed by our observation in
human breast cancer tissue specimens that the levels of
miR-214 were negatively correlated with UCP2. Overex-
pression of UCP2 contributed to endocrine resistance
against TAM/FUL. We thus concluded that miR-214
inhibited the TAM/FUL induced autophagy through
suppression of UCP2. MiR-214 might be developed as
a novel strategy for overcoming endocrine resistance
in breast cancers. These results provided new insights
into the mechanism of endocrine resistance by modu-
lation of autophagy.
Autophagy is an evolutionarily conserved catabolic
process for degradation of cytoplasmic components in-
cluding defective organelles and proteins. Physiologic-
ally, autophagy is implicated in cellular homeostasis by
recycling of nutrients whereas defect of autophagy is as-
sociated with cancers [30, 31]. Autophagy can act as a
pro-survival mechanism or as an alternative cell death
pathway to apoptosis [28]. Despite duality of autophagy,
accumulated evidence revealed an important role of au-
tophagy in the development of endocrine resistance in
the ER+ breast cancers [18]. Recent studies showed that
the inhibition of autophagy might increase the 4-OHT-
induced cytotoxicity whereas increase of autophagy is
associated with endocrine resistance to 4-OHT [32].
In breast cancer cells, inhibition of autophagy by 3-
MA or beclin-1 siRNA potentiated the resensitization
of previously antiestrogen resistant breast cancer cells
[6, 14], suggesting a pro-survival role of autophagy in
anti-estrogen therapy.
(See figure on previous page.)
Fig. 5 UCP2 modulated the 4-OHT/FUL-induced apoptosis in breast cancer cells. a-c MCF7 cells were transfected with UCP2 plasmid and empty
vector pcDNA3.1 or 200 nM siRNA of UCP2 for 48 h. RT-qPCR and Western blotting were performed to determine the expression of UCP2. The
ratio UCP2/β-actin is quantified (**P < 0.01 vs. empty vector control). d The immunofluorescence assay was performed to analyze the expression
and location of UCP2 in MCF7 cells. e Annexin V-PI staining assay was performed to determine apoptosis in MCF7 cells. Bar graphs indicated the
percentage of apoptotic cells. **P < 0.01 vs. negative control (NC) or empty vector control (pcDNA3.1)
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MiRNAs are involved in the regulation of many autoph-
agic processes, including autophagy induction, vesicle nu-
cleation and vesicle elongation and fusion, which provides
a potential for combining miRNA-based manipulation of
autophagy with therapy resistance in cancers [33]. Inhib-
ition of beclin 1-mediated autophagy by miR-30d mimic
Fig. 6 UCP2 modulated autophagy through activation of the PI3K-Akt-mTOR pathway. a MCF7/LCC9 cells were transfected with UCP2 plasmid or
siRNA of UCP2 for 48 h. Western blotting was performed to analyze the expression of cleaved LC3 and the ratio of Bax/Bcl-2. Bar graphs indicated
the relative levels of LC3-II and ratio of Bax/Bcl-2 normalized to β-actin. *P < 0.05, **P < 0.01 vs. control. ##P < 0.01 vs. vehicle control. b MCF7 cells
were cotransfected with GFP-LC3 together with UCP2 plasmid or 200 nM siRNA of UCP2 for 48 h. Cells were imaged under a confocal microscopy
(scale bar = 10 μm). Numbers of GFP-LC3 puncta per cell were counted (**P < 0.01 vs. empty vector control or negative control, n = 10). c Western
blotting was performed to analyze p-Akt, Akt, p-mTOR, mTOR in MCF7/LCC9 cells. β-actin was served as loading control. Bar graphs indicated the
relative levels of p-Akt/Akt and p-mTOR/mTOR normalized to β-actin. **P< 0.01 vs. empty vector control or negative control, ##P < 0.01 vs. vehicle control
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sensitized anaplastic thyroid carcinoma cells to cisplatin
[34]. MiR-101 suppressed the tamoxifen-induced autoph-
agy and increased the sensitivity of breast cancer cells to
tamoxifen [19]. In this study, miR-214 was found to
sensitize breast cancer cells to 4-OHT or FUL by inhib-
ition of autophagy.
Accumulating studies have shed light on the potential
of miR-214 as the therapeutic strategy for cancers. MiR-
214 was found downregulated in breast cancers [22].
MiR-214 might play pleiotropic and pivotal roles in re-
sistance or sensitivity in various cancers. On one hand,
high level of miR-214 enhanced the stemness and che-
moresistance in ovarian cancers by targeting p53/Nanog
[35]. MiR-214 might be responsible for chemoresistance
to cisplatin or gefitinib in ovarian cancer and non small
cell lung cancer [36, 37]. On the other hand, miR-214
enhanced the cisplatin-induced cytotoxicity through
down-regulation of Bcl2l2 in cervical cancer cells
[38]. In this study, miR-214 was found downregu-
lated in human breast cancer tissues and decreased
in response to 4-OHT/FUL. Our results showed that
reduction of miR-214 was associated with elevated
autophagy and endocrine resistance, while overex-
pression of miR-214 represses both basal and the 4-
OHT/FUL-induced autophagy. Further study showed
that miR-214 might reduce autophagy by directly
targeting UCP2.
UCP2 is a member of the family of uncoupling pro-
teins located in inner mitochondrial membrane. UCP2 is
involved in uncoupling oxidative phosphorylation and
facilitating energy dissipation as heat [39]. Overexpres-
sion of UCP2 conferred drug resistance to chemotherapy
and a higher survival through downregulation of ROS
[40, 41]. UCP2 was thus recognized as a negative regula-
tor of mitochondrial ROS in many type of cancers [42].
Overexpression of UCP2 decreased intracellular ROS
and attenuated apoptosis in HepG2 hepatoma cells in-
duced by various challenges [43]. Overexpression of UCP2
protected cancer cells from the gemcitabine-induced
apoptosis through decrease of mitochondrial superoxide
[44]. Inhibition of UCP2 enhanced the cisplatin-induced
cytotoxicity in colon cancer cells. UCP2 has been identi-
fied as a potential target for overcoming cancer chemore-
sistance [45]. In this study, breast cancer cells with
knockdown of UCP2 showed higher sensitivity to 4-OHT
than negative control cells in induction of apoptosis,
whereas overexpression of UCP2 attenuated the activity of
4-OHT. Further study showed that UCP2 might play a
crucial role in the induction of autophagy that confers the
endocrine resistance in the TAM and FUL cross-resistant
MCF7/LCC9 cells.
Recently, the PI3K/AKT/mTOR signaling pathway,
which transmits signals from cell membrane into nu-
cleus and activates multiple oncogenic programs, has
been reported to play an important role in the regulation
of autophagy in breast cancer cells. This signaling path-
way is hyperactive in more than 70 % of breast cancers.
It has been revealed that the PI3K/AKT/mTOR signal-
ing modulates the function of estrogen receptor. Activa-
tion of the PI3K-AKT-mTOR signaling is relevant to the
escape of cancer cells from endocrine therapy by inhibit-
ing the proapoptotic proteins and therefore contributes
to endocrine resistance [46, 47]. Hence, the protein ki-
nases located along this signaling pathway represent very
promising drug targets for breast cancer therapy. In this
study, UCP2 was found overexpressed in breast cancer
Fig. 7 A summary of the relationships between miR-214, UCP2, beclin-1, LC3-II, Bax, Caspase-9, PARP, and PI3K-Akt-mTOR after TAM/FUL
treatment. TAM/FUL treatment results in autophagy as well as apoptosis. MiR-214 increased the sensitivity of breast cancer cells to the
4-OHT/FUL-induced apoptosis through inhibition of autophagy. UCP2 was identified to be a direct target of miR-214. Overexpression of
UCP2 inhibited TAM/FUL-induced cell apotosis by increasing autophagy possibly through activation of the PI3K-Akt-mTOR signaling pathway,
thereby contributing to endocrine resistance
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tissue specimens. Overexpression of UCP2 induced au-
tophagy and endocrine resistance through phosphoryl-
ation of Akt and mTOR. These results suggested that
the activation of the PI3K-Akt-mTOR signaling pathway
might contribute to the UCP2-mediated autophagy in
breast cancers. Nonetheless, there were some contradict-
ory reports that inhibition of the PI3K-Akt-mTOR sig-
naling pathway induced autophagy in cancer cells [12].
It has been well established that ROS modulated the au-
tophagy process in cancer progression and chemother-
apy [48, 49]. It is hypothesized that regulation of UCP2,
a critical mitochondrial protein involved in ROS produc-
tion, might play a key role in coordinating autophagy
and endocrine resistance through the PI3K-Akt-mTOR
signaling pathway [50]. Based on currently available
information, we have proposed a schematic model be-
tween miR-214, UCP2, beclin-1, LC3-I/II, Bax, Caspase-
9, PARP, and Akt/mTOR in the regulation of autophagy
and apoptosis after TAM/FUL treatment (Fig. 7). Fur-
ther studies are underway to elucidate the mechanism of
UCP2-mediated autophagy in breast cancers.
Conclusion
In summary, TAM and FUL treatment induced apop-
tosis as well as autophagy in the ER+ breast cancer cells.
Autophagy is a major cause of resistance to TAM and
FUL. MiR-214 increased the sensitivity of breast cancers
to TAM and FUL through inhibition of autophagy by
targeting UCP2. MiR-214 could be developed as a novel
potential therapeutic strategy for overcoming endocrine
resistance in the ER+ breast cancers.
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